Logo image of MBX

MBX BIOSCIENCES INC (MBX) Stock Fundamental Analysis

NASDAQ:MBX - Nasdaq - US55287L1017 - Common Stock - Currency: USD

13.75  +0.5 (+3.77%)

Fundamental Rating

3

MBX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for MBX as it has an excellent financial health rating, but there are worries on the profitability. MBX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MBX had negative earnings in the past year.
MBX had a negative operating cash flow in the past year.
MBX Yearly Net Income VS EBIT VS OCF VS FCFMBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -29.87%, MBX perfoms like the industry average, outperforming 53.09% of the companies in the same industry.
MBX's Return On Equity of -31.21% is fine compared to the rest of the industry. MBX outperforms 62.37% of its industry peers.
Industry RankSector Rank
ROA -29.87%
ROE -31.21%
ROIC N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBX Yearly ROA, ROE, ROICMBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60

1.3 Margins

MBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBX Yearly Profit, Operating, Gross MarginsMBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, MBX has more shares outstanding
There is no outstanding debt for MBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MBX Yearly Shares OutstandingMBX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
MBX Yearly Total Debt VS Total AssetsMBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

MBX has an Altman-Z score of 24.42. This indicates that MBX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 24.42, MBX belongs to the best of the industry, outperforming 92.78% of the companies in the same industry.
MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.42
ROIC/WACCN/A
WACCN/A
MBX Yearly LT Debt VS Equity VS FCFMBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 23.31 indicates that MBX has no problem at all paying its short term obligations.
MBX's Current ratio of 23.31 is amongst the best of the industry. MBX outperforms 93.30% of its industry peers.
MBX has a Quick Ratio of 23.31. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX has a Quick ratio of 23.31. This is amongst the best in the industry. MBX outperforms 93.30% of its industry peers.
Industry RankSector Rank
Current Ratio 23.31
Quick Ratio 23.31
MBX Yearly Current Assets VS Current LiabilitesMBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -470.40%.
EPS 1Y (TTM)-470.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-83.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MBX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.81% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y76.41%
EPS Next 2Y32.94%
EPS Next 3Y19.81%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBX Yearly EPS VS EstimatesMBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBX Price Earnings VS Forward Price EarningsMBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX Per share dataMBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

MBX's earnings are expected to grow with 19.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.94%
EPS Next 3Y19.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MBX BIOSCIENCES INC

NASDAQ:MBX (8/1/2025, 5:20:01 PM)

13.75

+0.5 (+3.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)N/A N/A
Inst Owners76.96%
Inst Owner Change-0.23%
Ins Owners3.12%
Ins Owner Change0.07%
Market Cap459.52M
Analysts86.67
Price Target38.25 (178.18%)
Short Float %21.36%
Short Ratio13.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.77%
Min EPS beat(2)8.71%
Max EPS beat(2)18.83%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.27%
PT rev (3m)0.27%
EPS NQ rev (1m)-0.46%
EPS NQ rev (3m)-5.65%
EPS NY rev (1m)0%
EPS NY rev (3m)3.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.95
P/tB 1.95
EV/EBITDA N/A
EPS(TTM)-3.22
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS0
BVpS7.04
TBVpS7.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.87%
ROE -31.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.9%
ROA(5y)N/A
ROE(3y)-42.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 231.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.31
Quick Ratio 23.31
Altman-Z 24.42
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)409.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-470.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-83.26%
EPS Next Y76.41%
EPS Next 2Y32.94%
EPS Next 3Y19.81%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.91%
EBIT Next 3Y-23.74%
EBIT Next 5YN/A
FCF growth 1Y-73.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71%
OCF growth 3YN/A
OCF growth 5YN/A